Tenaya Therapeutics provides updates on its TN-201 gene therapy project targeting MYBPC3-related HCM.

ARTHEx Biotech has initiated dosing for the first patient in the Phase I-IIa trial of ArthemiR™ for Myotonic Dystrophy Type 1 (DM1).

In the development of antibody-drug conjugates (ADCs), selecting an appropriate linker is a critical factor that determines the efficacy and safety of the final product.

BioAegis Therapeutics has initiated its Phase 2 clinical trial for Gelsolin, an immune modulator, by enrolling its first patient to address Acute Respiratory Distress Syndrome (ARDS).

Poseida Therapeutics focuses on developing unique non-viral therapies for individuals suffering from cancer, autoimmune disorders, and rare diseases.

The U.S. FDA has authorized VYALEV™ (foscarbidopa and foslevodopa) for adults with advanced Parkinson’s disease.

Response Pharmaceuticals has begun enrolling its first patients in a Phase 2 trial for RDX-002, a new small molecule iMTP inhibitor, targeting individuals stopping GLP-1 agonists.

Clarametyx Biosciences reveals advancements in research on CMTX-101 antibody treatment for cystic fibrosis-related infections.

Bright Peak Therapeutics has initiated dosing for the first patient in the Phase 1/2a clinical trial of BPT567, an innovative bifunctional PD1-IL18 immunoconjugate.

Wave Life Sciences reports the first successful therapeutic RNA editing in humans during the RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency.

Latigo Biotherapeutics has administered the first dose to a participant in its Phase 1 clinical trial for LTG-305, aimed at non-opioid pain management.

The role of Artificial Intelligence (AI) in the design of small nucleic acid drugs is becoming increasingly prominent.